280 related articles for article (PubMed ID: 29753531)
1. Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials.
Iwatsubo T; Iwata A; Suzuki K; Ihara R; Arai H; Ishii K; Senda M; Ito K; Ikeuchi T; Kuwano R; Matsuda H; ; Sun CK; Beckett LA; Petersen RC; Weiner MW; Aisen PS; Donohue MC;
Alzheimers Dement; 2018 Aug; 14(8):1077-1087. PubMed ID: 29753531
[TBL] [Abstract][Full Text] [Related]
2. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
3. Effect of apolipoprotein E ε4 allele on the progression of cognitive decline in the early stage of Alzheimer's disease.
Suzuki K; Hirakawa A; Ihara R; Iwata A; Ishii K; Ikeuchi T; Sun CK; Donohue M; Iwatsubo T;
Alzheimers Dement (N Y); 2020; 6(1):e12007. PubMed ID: 32211510
[TBL] [Abstract][Full Text] [Related]
4. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505
[TBL] [Abstract][Full Text] [Related]
5. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.
Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Liu E; Morris JC; Petersen RC; Saykin AJ; Schmidt ME; Shaw L; Shen L; Siuciak JA; Soares H; Toga AW; Trojanowski JQ;
Alzheimers Dement; 2013 Sep; 9(5):e111-94. PubMed ID: 23932184
[TBL] [Abstract][Full Text] [Related]
6. Lower Serum Calcium as a Potentially Associated Factor for Conversion of Mild Cognitive Impairment to Early Alzheimer's Disease in the Japanese Alzheimer's Disease Neuroimaging Initiative.
Sato K; Mano T; Ihara R; Suzuki K; Tomita N; Arai H; Ishii K; Senda M; Ito K; Ikeuchi T; Kuwano R; Matsuda H; Iwatsubo T; Toda T; Iwata A;
J Alzheimers Dis; 2019; 68(2):777-788. PubMed ID: 30814351
[TBL] [Abstract][Full Text] [Related]
7. Current Landscape of Late-Phase Clinical Trials for Alzheimer's Disease: Comparing Regional Variation Between Subjects in Japan and North America.
Kikuchi M; Adachi N; Matsumaru N; Tsukamoto K
Pharmaceut Med; 2019 Dec; 33(6):511-518. PubMed ID: 31933241
[TBL] [Abstract][Full Text] [Related]
8. Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans.
Aisen PS; Petersen RC; Donohue MC; Gamst A; Raman R; Thomas RG; Walter S; Trojanowski JQ; Shaw LM; Beckett LA; Jack CR; Jagust W; Toga AW; Saykin AJ; Morris JC; Green RC; Weiner MW;
Alzheimers Dement; 2010 May; 6(3):239-46. PubMed ID: 20451872
[TBL] [Abstract][Full Text] [Related]
9. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects.
Trojanowski JQ; Vandeerstichele H; Korecka M; Clark CM; Aisen PS; Petersen RC; Blennow K; Soares H; Simon A; Lewczuk P; Dean R; Siemers E; Potter WZ; Weiner MW; Jack CR; Jagust W; Toga AW; Lee VM; Shaw LM;
Alzheimers Dement; 2010 May; 6(3):230-8. PubMed ID: 20451871
[TBL] [Abstract][Full Text] [Related]
10. Introduction to special issue: Overview of Alzheimer's Disease Neuroimaging Initiative.
Weiner MW; Veitch DP
Alzheimers Dement; 2015 Jul; 11(7):730-3. PubMed ID: 26194308
[TBL] [Abstract][Full Text] [Related]
11. Amyloid deposition, hypometabolism, and longitudinal cognitive decline.
Landau SM; Mintun MA; Joshi AD; Koeppe RA; Petersen RC; Aisen PS; Weiner MW; Jagust WJ;
Ann Neurol; 2012 Oct; 72(4):578-86. PubMed ID: 23109153
[TBL] [Abstract][Full Text] [Related]
12. [Current topics about mild cognitive impairment (MCI)].
Yamamoto Y
Seishin Shinkeigaku Zasshi; 2011; 113(6):584-92. PubMed ID: 21815470
[TBL] [Abstract][Full Text] [Related]
13. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.
Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Liu E; Morris JC; Petersen RC; Saykin AJ; Schmidt ME; Shaw L; Siuciak JA; Soares H; Toga AW; Trojanowski JQ;
Alzheimers Dement; 2012 Feb; 8(1 Suppl):S1-68. PubMed ID: 22047634
[TBL] [Abstract][Full Text] [Related]
14. Identification of prognostic factors to predict cognitive decline of patients with early Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative study.
Yagi T; Kanekiyo M; Ito J; Ihara R; Suzuki K; Iwata A; Iwatsubo T; Aoshima K; ;
Alzheimers Dement (N Y); 2019; 5():364-373. PubMed ID: 31440579
[TBL] [Abstract][Full Text] [Related]
15. Japanese Alzheimer's Disease Neuroimaging Initiative: present status and future.
Iwatsubo T
Alzheimers Dement; 2010 May; 6(3):297-9. PubMed ID: 20451880
[TBL] [Abstract][Full Text] [Related]
16. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
[TBL] [Abstract][Full Text] [Related]
17. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
[TBL] [Abstract][Full Text] [Related]
18. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
[TBL] [Abstract][Full Text] [Related]
19. Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.
Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
Alzheimers Dement; 2017 Apr; 13(4):e1-e85. PubMed ID: 28342697
[TBL] [Abstract][Full Text] [Related]
20. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
